| Lisanne M Bzoskie, MD | |
|
9400 Rosecrans Ave, Bellflower, CA 90706-2246 | |
| (562) 461-3000 | |
| Not Available |
| Full Name | Lisanne M Bzoskie |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Neonatal-perinatal Medicine |
| Location | 9400 Rosecrans Ave, Bellflower, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003987926 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080N0001X | Pediatrics - Neonatal-perinatal Medicine | G73920 (California) | Primary |
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing eleven new Collaborative Research Centers (CRC) to promote world-class research at universities. This was announced by the relevant Grants Committee, which met by video conference due to the coronavirus pandemic.
Dr. Jeff Winternheimer of the Illinois Back Institute has developed a revolutionary non-surgical procedure to alleviate back pain. Both professional athletes and everyday back and neck pain sufferers have been flocking to his four Chicago area clinics to see for themselves.
Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lisanne M Bzoskie, MD 9400 Rosecrans Ave, Bellflower, CA 90706-2246 Ph: (562) 461-3000 | Lisanne M Bzoskie, MD 9400 Rosecrans Ave, Bellflower, CA 90706-2246 Ph: (562) 461-3000 |
News Archive
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing eleven new Collaborative Research Centers (CRC) to promote world-class research at universities. This was announced by the relevant Grants Committee, which met by video conference due to the coronavirus pandemic.
Dr. Jeff Winternheimer of the Illinois Back Institute has developed a revolutionary non-surgical procedure to alleviate back pain. Both professional athletes and everyday back and neck pain sufferers have been flocking to his four Chicago area clinics to see for themselves.
Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).
› Verified 4 days ago
Ms. Maria V Pamaran, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 10230 E Artesia Blvd, #302, Bellflower, CA 90706 Phone: 562-461-7588 Fax: 562-461-7478 | |
Ann K. Kershnar, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000 | |
Nancy Ramos, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000 | |
Jeffrey S. Mallin, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000 | |
Mi-kyung Lee, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000 | |
Sunmee Chung, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9400 Rosecrans Ave, Bellflower, CA 90706 Phone: 562-461-3000 |